Trevena, Inc. Banner Image

Trevena, Inc.

  • Ticker TRVN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Trevena, Inc. Logo Image
  • 11-50 Employees
  • Based in Chesterbrook, Pennsylvania
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYKâ„¢ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments areMore inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
4.8 / 5.0 (160)

Trevena, Inc. reports have an aggregate usefulness score of 4.8 based on 160 reviews.

Trevena, Inc.

Most Recent Annual Report

Trevena, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Trevena, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!